Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study

PHASE2TerminatedINTERVENTIONAL
Enrollment

198

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Fostamatinib

Fostamatinib 100mg twice daily.

DRUG

Adalimumab

Adalimumab 40 mg by subcutaneous injection every 2 weeks for 24 weeks.

DRUG

Placebo of Fostamatinib

Placebo bid for 6 weeks.

DRUG

Placebo of Adalimumab

Placebo injection once every two weeks.

Trial Locations (21)

Unknown

Research Site, Glendale

Research Site, Paradise Valley

Research Site, Phoenix

Research Site, Brooklyn

Research Site, Jackson

Research Site, Austin

Research Site, Pleven

Research Site, Mississauga

Research Site, Prague

Research Site, Hamburg

Research Site, Munich

Research Site, Balatonfüred

Research Site, Budapest

Research Site, Amsterdam

Research Site, Warsaw

Research Site, Yaroslavl

Research Site, Durban

Research Site, Pretoria

Research Site, Stellenbosch

Research Site, Manchester

Research Site, Oxford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY